Euroapi S.A. (EAPI.PA) Stock Analysis & Winston Score

Euroapi is a French company that makes the active ingredients found inside medicines. These ingredients, called APIs (active pharmaceutical ingredients), are the chemical compounds that actually do the work in drugs like antibiotics, hormones, and treatments for chronic diseases. Euroapi sells primarily to pharmaceutical companies across Europe, which use these ingredients to manufacture finished pills, injections, and other medications. The company earns revenue by manufacturing and selling these chemical ingredients to drug makers under supply contracts. Euroapi operates mainly in Europe, with production sites in France, Hungary, Germany, and other countries, and generated roughly €900 million in annual sales at its peak. It was spun off from Sanofi in 2022, which gave it an initial customer base but also left it dependent on winning new clients to grow independently. The main challenge the company faces is improving its thin profit margins in a competitive, cost-sensitive industry where it is currently losing money at the operating level.